Dr. Wierda Discusses Sequencing New Agents in CLL
William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing new agents in chronic lymphocytic leukemia.
William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing new agents in chronic lymphocytic leukemia (CLL).
With a plethora of novel agents approved in CLL, sequencing has become a central topic of discussion.
Some updates include the approval of venetoclax (Venclexta), which Wierda says is being considered for combination with existing agents or possibly a CD20-targeted monoclonal antibody to get better remissions.
Related Videos
Related Content
